Effects of Dietary Modification Based on Complementary and Alternative Iranian Medicine in Patients with Secondary-Progressive Multiple Sclerosis: A Randomized Controlled Clinical Trial

被引:3
|
作者
Moravejolahkami, Amir Reza [1 ]
Hadi, Saeid [1 ]
Hadi, Vahid [1 ]
Mirghazanfari, Sayid Mahdi [2 ]
Mohajeri, Mohsen [3 ,4 ]
机构
[1] AJA Univ Med Sci, Fac Med, Dept Hlth & Nutr, West Fatemi St, Tehran 1411718541, Iran
[2] AJA Univ Med Sci, Sch Med, Dept Physiol & Iranian Med, West Fatemi St, Tehran 1411718541, Iran
[3] AJA Univ Med Sci, Fac Med, Dept Persian Med, Tehran, Iran
[4] Iran Univ Med Sci, Sch Persian Med, Dept Tradit Med, Tehran, Iran
来源
关键词
diet therapy; complementary therapies; Persian medicine; secondary-progressive multiple sclerosis; randomized controlled trial; PRIMROSE OILS INTERVENTION; SUPPLEMENTED HEMP SEED; HOT-NATURE DIET; PERSIAN VERSION; QUESTIONNAIRE; RELIABILITY; THERAPIES; SYMPTOMS; VALIDITY;
D O I
10.1089/jicm.2023.0037
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Objectives: To evaluate the efficacy of dietary modifications based on complementary and alternative Iranian medicine (CAIM) in patients with secondary-progressive multiple sclerosis (SPMS).Design: In this randomized controlled trial, 70 SPMS patients were randomized to receive either a moderate-nature diet based on Persian medicine (as intervention) or usual diet plus health-related diet recommendations (as control) for 2 months. Serum high-sensitivity C-reactive protein (hs-CRP), erythrocyte sedimentation rate (ESR), Expanded Disability Status Scale (EDSS), Modified Fatigue Impact Scale (MFIS), State-Trait Anxiety Inventory (STAI), Global Pain Scale (GPS), Gastrointestinal Symptom Rating Scale (GSRS), anthropometric measurements, and quality of life (QOL) were assessed at baseline and end of trial. Analysis of covariance was performed, and the results were adjusted for potential confounders using SPSS v.14.Results: All participants completed the study for 2 months. There were significant improvements across the mean changes of hs-CRP (-0.1 +/- 0.2 mg/L for intervention vs. -0.01 +/- 0.13 mg/L for control; p(adjusted) = 0.012), MFIS (-11.0 +/- 11.8 vs. -0.7 +/- 9.9; p(adjusted) <0.001), GSRS (-19.9 +/- 16.3 to 1.2 +/- 17.5; p(adjusted) <0.001), GPS (p(adjusted) = 0.032), and QOL (p(adjusted) <0.05). No significant difference was observed across the ESR, EDSS, STAI, and anthropometric measurements.Conclusion: Dietary modifications based on CAIM may improve inflammation and clinical manifestations in SPMS patients. Nonetheless, further trials are required to confirm these findings.Clinical Trial Registration number: IRCT20181113041641N2.
引用
收藏
页码:747 / 756
页数:10
相关论文
共 50 条
  • [1] Complementary and Alternative Medicine in Iranian Multiple Sclerosis Patients
    Harirchian, M. H.
    Sahraian, M. A.
    Hosseinkhani, A.
    MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (04) : 537 - 537
  • [2] A Randomized Controlled Trial of Neuroprotection with Lamotrigine in Secondary Progressive Multiple Sclerosis
    Kapoor, Raju
    Furby, Julian
    Hayton, Thomas
    Smith, Kenneth
    Altmann, Daniel
    Brenner, Robert
    Chataway, Jeremy
    Hughes, Richard
    Miller, David
    NEUROLOGY, 2010, 74 (09) : A193 - A193
  • [3] Level of attitude toward complementary and alternative medicine among Iranian patients with multiple sclerosis
    Harirchian, Mohammad Hossein
    Sahraian, Mohammad Ali
    Hosseinkhani, Amir
    Amirzargar, Nasibeh
    IRANIAN JOURNAL OF NEUROLOGY, 2014, 13 (01) : 13 - 18
  • [4] Rituximab and glatiramer acetate in secondary progressive multiple sclerosis: A randomized clinical trial
    Cheshmavar, Masoumeh
    Mirmosayyeb, Omid
    Badihian, Negin
    Badihian, Shervin
    Shaygannejad, Vahid
    ACTA NEUROLOGICA SCANDINAVICA, 2021, 143 (02): : 178 - 187
  • [5] Comparison of the efficacy of rituximab and glatiramer acetate in patients with active secondary progressive multiple sclerosis: A randomized clinical trial
    Mirmosayyeb, Omid
    Cheshmavar, Masoume
    Badihian, Negin
    Badihian, Shervin
    Shaygannejad, Vahid
    Ashtari, Fereshteh
    NEUROLOGY, 2020, 94 (15)
  • [6] Do Secondary Progressive Multiple Sclerosis patients benefit from Computer- based cognitive neurorehabilitation? A randomized sham controlled trial
    Messinis, Lambros
    Kosmidis, Mary H.
    Nasios, Grigorios
    Konitsiotis, Spyridon
    Ntoskou, Aikaterini
    Bakirtzis, Christos
    Grigoriadis, Nikolaos
    Patrikelis, Panayiotis
    Panagiotopoulos, Elias
    Gourzis, Philippos
    Malefaki, Sonia
    Papathanasopoulos, Panagiotis
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 39
  • [7] How do patients with secondary progressive multiple sclerosis enrolled in the EXPAND randomized controlled trial compare with those seen in German clinical practice in the NeuroTransData multiple sclerosis registry?
    Braune, Stefan
    Bergmann, Arnfin
    Bezlyak, Vladimir
    Adlard, Nicholas
    JOURNAL OF CENTRAL NERVOUS SYSTEM DISEASE, 2022, 14
  • [8] Evaluating the Role of Corticosteroid Pulse Therapy in Patients With Secondary Progressive Multiple Sclerosis Receiving Mitoxantrone: A Double Blind Randomized Controlled Clinical Trial
    Rahimdel, Abolghasem
    Zeinali, Ahmad
    Mellat, Ali
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2015, 17 (10)
  • [9] Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis A Randomized, Controlled Trial
    Chow, Helene Hojsgaard
    Talbot, Jacob
    Lundell, Henrik
    Madsen, Camilla Gobel
    Marstrand, Lisbet
    Lange, Theis
    Mahler, Mie Reith
    Buhelt, Sophie
    Hansen, Rikke Holm
    Blinkenberg, Morten
    Christensen, Jeppe Romme
    Sorensen, Per Soelberg
    von Essen, Marina Rode
    Siebner, Hartwig Roman
    Sellebjerg, Finn
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2021, 8 (05):
  • [10] Observed differences in characteristics of secondary-progressive multiple sclerosis and relapsing-remitting multiple sclerosis patients in the US-based Corrona MS Registry
    Kantor, Daniel
    Bebo, Bruce
    Coyle, Patricia
    Fox, Edward
    Bermel, Robert
    Greenberg, Jeffrey
    Malley, Wendi
    McLean, Robert
    Rebello, Sabrina
    LaRocca, Nicholas
    Miller, Aaron
    NEUROLOGY, 2020, 94 (15)